Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1381 to 1395 of 1426 results for primary care

  1. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

  2. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1060)

    Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

  3. Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)

    Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults

  4. Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)

    Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

  5. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.

  6. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

  7. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

    Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

  8. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.

  9. Living-donor liver transplantation (HTG390)

    Evidence-based recommendations on living-donor liver transplantation. This involves replacing a diseased or damaged liver with a healthy one from a living human donor.

  10. Cellulitis and erysipelas: antimicrobial prescribing (NG141)

    This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.

  11. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

  12. Integrated patient information systems:- What is the clinical and cost effectiveness of different methods for integrating patient information throughout the emergency medical care pathway?

    methods for integrating patient information throughout the emergency medical care pathway? Any explanatory notes(if applicable) Why this...

  13. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)

    Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.

  14. ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation (MIB61)

    NICE has developed a medtech innovation briefing (MIB) on the ThermoCool SmartTouch catheter for percutaneous radiofrequency ablation in atrial fibrillation

  15. First HIV prevention injection for people unable to have daily PrEP recommended

    A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.